U.S. Carbapenem Market Size & Outlook, 2022-2030
U.S. carbapenem market, 2018-2030 (US$M)
Related Markets
U.S. carbapenem market highlights
- The U.S. carbapenem market generated a revenue of USD 1,334.6 million in 2022 and is expected to reach USD 1,785.6 million by 2030.
- The U.S. market is expected to grow at a CAGR of 3.7% from 2023 to 2030.
- In terms of segment, meropenem was the largest revenue generating drug class in 2022.
- Meropenem is the most lucrative drug class segment registering the fastest growth during the forecast period.
Carbapenem market data book summary
| Market revenue in 2022 | USD 1,334.6 million |
| Market revenue in 2030 | USD 1,785.6 million |
| Growth rate | 3.7% (CAGR from 2022 to 2030) |
| Largest segment | Meropenem |
| Fastest growing segment | Meropenem |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Meropenem, Imipenem, Ertapenem, Others Drug Class |
| Key market players worldwide | Menarini Group, Pfizer Inc, Sun Pharmaceutical Industries, Lupin, Aurobindo Pharma, Merck & Co Inc, Venus Group |
Other key industry trends
- In terms of revenue, U.S. accounted for 36.9% of the global carbapenem market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. carbapenem market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 193.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Carbapenem Market Scope
Carbapenem Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. carbapenem market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to carbapenem market will help companies and investors design strategic landscapes.
Meropenem was the largest segment with a revenue share of 54.8% in 2022. Horizon Databook has segmented the U.S. carbapenem market based on meropenem, imipenem, ertapenem, others drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. carbapenem market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. carbapenem market databook
-
Our clientele includes a mix of carbapenem market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. carbapenem market, including forecasts for subscribers. This country databook contains high-level insights into U.S. carbapenem market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. carbapenem market report size, by drug class, 2018-2030 (US$M)
U.S. Carbapenem Market Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
